Cargando…

Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors

The chimeric antibodies anti-CD20 rituximab (Rtx) and anti-TNFα infliximab (Ifx) induce antidrug antibodies (ADAs) in many patients with inflammatory diseases. Because of the key role of CD4 T lymphocytes in the initiation of antibody responses, we localized the CD4 T cell epitopes of Rtx and Ifx. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamze, Moustafa, Meunier, Sylvain, Karle, Anette, Gdoura, Abdelaziz, Goudet, Amélie, Szely, Natacha, Pallardy, Marc, Carbonnel, Franck, Spindeldreher, Sebastian, Mariette, Xavier, Miceli-Richard, Corinne, Maillère, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418239/ https://www.ncbi.nlm.nih.gov/pubmed/28529511 http://dx.doi.org/10.3389/fimmu.2017.00500

Ejemplares similares

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
por: Spindeldreher, Sebastian, et al.
Publicado: (2020)

Identification and Characterization of Circulating Naïve CD4+ and CD8+ T Cells Recognizing Nickel
por: Bechara, Rami, et al.
Publicado: (2019)

Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)

Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)

Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016)

Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
por: Sordé, Laetitia, et al.
Publicado: (2017)

Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
por: Sordé, Laetitia, et al.
Publicado: (2017)

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
por: de Bourayne, Marie, et al.
Publicado: (2022)

Models of Dendritic Cells to Assess Skin Sensitization
por: Hardonnière, Kévin, et al.
Publicado: (2022)

Low Percentage of Signal Regulatory Protein α/β(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
por: Magill, Laura, et al.
Publicado: (2018)

P17-18. ANRS lipo5 sequences induce in vitro cross-reactive CD4+ T cell response against clade B and C
por: Castelli, FA, et al.
Publicado: (2009)

Specificity of the T Cell Response to Protein Biopharmaceuticals
por: Meunier, Sylvain, et al.
Publicado: (2020)

Combined Infliximab and Rituximab in Necrotising Scleritis
por: Morarji, Jiten, et al.
Publicado: (2012)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

How to Address the Adjuvant Effects of Nanoparticles on the Immune System
por: Feray, Alexia, et al.
Publicado: (2020)

Infliximab/rituximab: COVID-19 infection: 10 case reports
Publicado: (2022)

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab
por: Melong Pianta Taleng, Cathy Mireille, et al.
Publicado: (2021)

The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles
por: Reynolds, Catherine J, et al.
Publicado: (2014)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Direct brain involvement of Takayasu arteritis treated with rituximab and infliximab: a case report
por: Kim, Seondeuk, et al.
Publicado: (2022)

Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
por: Valor-Méndez, Larissa, et al.
Publicado: (2021)

B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera
por: Homann, Arne, et al.
Publicado: (2015)

Shared epitope and rheumatoid arthritis severity: association with infliximab treatment in a postmarketing study
por: Marotte, H, et al.
Publicado: (2003)

CD8α(+)β(−) and CD8α(+)β(+) plasmacytoid dendritic cells induce Foxp3(+) regulatory T cells and prevent the induction of airway hyperreactivity
por: Lombardi, Vincent, et al.
Publicado: (2012)

A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors
por: Webster, Carl I., et al.
Publicado: (2016)

Safety of rituximab in children with auto-immune diseases
por: Bader-Meunier, B, et al.
Publicado: (2008)

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses
por: Azam, Aurélien, et al.
Publicado: (2021)

Human CD4 T cell epitopes selective for Vaccinia versus Variola virus
por: Probst, Alicia, et al.
Publicado: (2013)

Applying MAPPs Assays to Assess Drug Immunogenicity
por: Karle, Anette C.
Publicado: (2020)

Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
por: Rombach-Riegraf, Verena, et al.
Publicado: (2014)

Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold
por: Pruvost, Tiphanie, et al.
Publicado: (2023)

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
por: Bitoun, Samuel, et al.
Publicado: (2023)

Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates
por: Morgan, Hannah, et al.
Publicado: (2019)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

CTLA-4 polymorphism and primary Sjögren's syndrome: authors' response
por: Miceli-Richard, Corinne, et al.
Publicado: (2007)

Exploring the Potential of the Model Cyanobacteria Synechococcus PCC 7002 and PCC 7942 for the Photoproduction of High-Value Terpenes: A Comparison with Synechocystis PCC 6803
por: Chenebault, Célia, et al.
Publicado: (2023)

Successful treatment of IgG4‐related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab
por: Seegobin, Karan, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7217s53f8ppj01adtl614l97po